Citations

Mayo Clinic

Showing 10 of 108599 citations.

Faculty Opinions recommendation of Outcomes of simultaneous major liver resection and colorectal surgery for colorectal liver metastases.
Chua, Heidi K

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 20, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.726067139.793531035 Get It

Faculty Opinions recommendation of Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus.
Chua, Heidi K

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 20, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.725837306.793531033 Get It

Faculty Opinions recommendation of Early recurrence after liver resection for colorectal metastases: risk factors, prognosis, and treatment. A LiverMetSurvey-based study of 6,025 patients.
Chua, Heidi K

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 20, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.718208800.793531039 Get It

The Incidence of and Risk Factors for Postintubation Hypotension in the Immunocompromised Critically Ill Adult
Seisa, Mohamed O. , Cambest, John, Wiegand, Robert A., Busack, Kyle D., Loftsgard, Theodore O. , Schroeder, Darrell R. , Diedrich, Daniel A. , Smischney, Nathan J. , Schroeder, Darrell

Journal of Intensive Care Medicine | April 20, 2017 | Volume: 34 | Issue: 7 | Pages: 578-586

10.1177/0885066617704844 | PMID 28425335 Get It

Objectives: Our primary aim was to ascertain the frequency of postintubation hypotension in immunocompromised critically ill adults with secondary aims of arriving at potential risk factors for the development of postintubation hypotension and its impact on patient-related outcomes. Methods: Critically ill adult patients (≥18 years) were included from January 1, 2010, to December 31, 2014. We defined immunocompromised as patients with any solid organ or nonsolid organ malignancy or transplant, whether solid organ or not, requiring current chemotherapy. Postintubation hypotension was defined as a decrease in systolic blood pressure to less than 90 mm Hg or a decrease in mean arterial pressure to less than 65 mm Hg or the initiation of any vasopressor medication. Patients were then stratified based on development of postintubation hypotension. Potential risk factors and intensive care unit (ICU) outcome metrics were electronically captured by a validated data mart system. Results: The final cohort included 269 patients. Postintubation hypotension occurred in 141 (52%; 95% confidence interval: 46-58) patients. Several risk factors predicted postintubation hypotension on univariate analysis; however, only Acute Physiology and Chronic Health Evaluation III score in the first 24 hours, preintubation shock status, and preintubation hemodynamic instability remained significant on all 4 multivariate analyses. Patients developing postintubation hypotension had higher ICU and hospital mortality (54 [38%] vs 31 [24%], P = .01; 69 [49%] vs 47 [37%], P = .04). Conclusion: Based on previous literature, we found a higher frequency of postintubation hypotension in the immunocompromised than in the nonimmunocompromised critically ill adult patients. Acute Physiology and Chronic Health Evaluation III score in the first 24 hours, preintubation shock status, and preintubation hemodynamic instability were significant predictors on multivariate analyses. Postintubation hypotension led to higher ICU and hospital mortality in those experiencing this complication.
Recurrent myxoinflammatory fibroblastic sarcoma: a case report
Jagadesh, Niveditha , Miller, Daniel , Schenk, William B., Attia, Steven , Sherman, Courtney E. , Cortese, Cherise , May, Byron C. , Miller, Daniel H , Schenk, William, Miller, Robert C.

Clinical Case Reports | April 20, 2017 | Volume: 5 | Issue: 6 | Pages: 871-875

10.1002/ccr3.949 | PMID 28588829 Get It

Key Clinical Message Myxoinflammatory fibroblastic sarcoma is a rare sarcoma which typically presents in the extremities and is treated by definitive surgery. In recurrent disease, the reported utilization of radiotherapy is increasing, and more modern techniques such as intensity‐modulated radiotherapy may be improving long‐term outcomes.
Nrf2, cellular redox regulation, and neurologic implications
Benarroch, Eduardo E.

Neurology | April 20, 2017 | Volume: 88 | Issue: 20 | Pages: 1942-1950

10.1212/wnl.0000000000003946 | PMID 28424271 Get It

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL
LaPlant, Betsy, Call, Timothy G. , Leis, José F., He, Rong , Wiseman, Gregory A., Lin, Yi , Asmus, Erik, Nowakowski, Grzegorz S. , Conte, Michael, Bowen, Deborah A., Aitken, Casey N., Dyke, Daniel L. Van , Greipp, Patricia T. , Wu, Xiaosheng , Secreto, Charla, Tian, Shulan , Braggio, Esteban , Wellik, Linda, Micallef, Ivana N. , Viswanatha, David S., Yan, Huihuang , Chanan‐Khan, Asher , Ansell, Stephen M. , LaPlant, Betsy R, Chanan-Khan, Asher A., Ding, Wei , Parikh, Sameer A. , Shanafelt, Tait D. , Sinha, Sutapa , Le‐Rademacher, Jennifer , Feldman, Andrew L. , Habermann, Thomas M. , Witzig, Thomas E. , Liu, Xin , Zhang, Henan , Kay, Neil E. , Dong, Haidong , Braggio, Esteban , Greipp, Patricia T , Lin, Yi

Blood | April 20, 2017 | Volume: 129 | Issue: 26 | Pages: 3419-3427

10.1182/blood-2017-02-765685 | PMID 28424162 Get It

Key Points Pembrolizumab was first shown to be clinically active in CLL patients with RT. PD-1 and PD-L1 expression in tumor microenvironment are promising biomarkers to select RT patients for PD-1 blockade.
Spatial intensity distribution analysis quantifies the extent and regulation of homodimerization of the secretin receptor
Pediani, John D. , Harikumar, Kaleeckal G. , Milligan, Graeme , Miller, Laurence J. , Ward, Richard John , Harikumar, Kaleeckal G

Biochemical Journal | April 20, 2017 | Volume: 474 | Issue: 11 | Pages: 1879-1895

10.1042/bcj20170184 | PMID 28424368 Get It

Previous studies have indicated that the G-protein-coupled secretin receptor is present as a homodimer, organized through symmetrical contacts in transmembrane domain IV, and that receptor dimerization is critical for high-potency signalling by secretin. However, whether all of the receptor exists in the dimeric form or if this is regulated is unclear. We used measures of quantal brightness of the secretin receptor tagged with monomeric enhanced green fluorescent protein (mEGFP) and spatial intensity distribution analysis to assess this. Calibration using cells expressing plasma membrane-anchored forms of mEGFP initially allowed us to demonstrate that the epidermal growth factor receptor is predominantly monomeric in the absence of ligand and while wild-type receptor was rapidly converted into a dimeric form by ligand, a mutated form of this receptor remained monomeric. Equivalent studies showed that, at moderate expression levels, the secretin receptor exists as a mixture of monomeric and dimeric forms, with little evidence of higher-order complexity. However, sodium butyrate-induced up-regulation of the receptor resulted in a shift from monomeric towards oligomeric organization. In contrast, a form of the secretin receptor containing a pair of mutations on the lipid-facing side of transmembrane domain IV was almost entirely monomeric. Down-regulation of the secretin receptor-interacting G-protein Gαs did not alter receptor organization, indicating that dimerization is defined specifically by direct protein–protein interactions between copies of the receptor polypeptide, while short-term treatment with secretin had no effect on organization of the wild-type receptor but increased the dimeric proportion of the mutated receptor variant.
Performing Percutaneous Coronary Intervention Without On-Site Cardiac Surgery Is Not a License for Percutaneous Coronary Intervention Instead of Coronary Artery Bypass Grafting—Reply
Rihal, Charanjit S. , Goel, Kashish , Gupta, Tanush , Rihal, Charanjit S.

JAMA Cardiology | April 19, 2017 | Volume: 2 | Issue: 8 | Pages: 926

10.1001/jamacardio.2017.0532 | PMID 28423142 Get It

Perioperative Vision Loss in Cervical Spinal Surgery
Gabel, Brandon, Lam, Arthur M., Chapman, Jens R. , Oskouian, Rod J. , Currier, Bradford L. , Sebastian, Arjun S. , Hamilton, Steven R., Fehlings, Michael G. , Mroz, Thomas E. , Nassr, Ahmad , Arnold, Paul M. , Riew, Kiehyun Daniel , Fehlings, Michael G

Global Spine Journal | April 19, 2017 | Volume: 7 | Issue: 1_suppl | Pages: 91S-95S

10.1177/2192568216688196 | PMID 28451500 Get It

Study Design: Retrospective multicenter case series. Objective: To assess the rate of perioperative vision loss following cervical spinal surgery. Methods: Medical records for 17 625 patients from 21 high-volume surgical centers from the AOSpine North America Clinical Research Network who received cervical spine surgery (levels from C2 to C7) between January 1, 2005, and December 31, 2011, inclusive, were reviewed to identify occurrences of vision loss following surgery. Results: Of the 17 625 patients in the registry, there were 13 946 patients assessed for the complication of blindness. There were 9591 cases that involved only anterior surgical approaches; the remaining 4355 cases were posterior and/or circumferential fusions. There were no cases of blindness or vision loss in the postoperative period reported during the sampling period. Conclusions: Perioperative vision loss following cervical spinal surgery is exceedingly rare.